Bhuvan Kishore

University Hospitals Birmingham NHS Foundation Trust — United Kingdom

Medicine · Health Sciences

18h-index1.3kcitations97works2.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(52), Protein Degradation and Inhibitors(27), Cancer Treatment and Pharmacology(18), Hematopoietic Stem Cell Transplantation(15), Peptidase Inhibition and Analysis(13)

Publications96 total

Is IMWG frailty-score-adjusted dosing the right approach to improve toxicity and outcomes in FRAIL patients? Results from the UK-MRA FiTNEss trial in newly diagnosed myeloma patients ineligible for ASCT.
Blood·2025
mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow
Blood Advances·2025· 1 citedOpen Access
<scp>NGS</scp> ‐based targeted sequencing guides risk‐adapted and molecularly targeted therapy decisions in multiple myeloma
British Journal of Haematology·2025Open Access
Cost-Effectiveness of Frailty-Adjusted Therapy in Transplant Non-Eligible Patients with Newly Diagnosed Multiple Myeloma - an Economic Evaluation of the Fitness Trial
Blood·2024Open Access
IMWG Frailty Score-Adjusted Therapy Delivery Reduces the Early Mortality Risk in Newly Diagnosed Tne Multiple Myeloma: Results of the UK Myeloma Research Alliance (UK-MRA) Myeloma XIV Fitness Trial
Blood·2024· 8 cited
Outcomes in patients with light chain cardiac amyloidosis undergoing heart transplantation: a single centre UK study
European Heart Journal·2024Open Access
P-064 Trial in Progress: A Retrospective Multi-Country Study of Clinical Outcomes in Patients with R/R Multiple Myeloma Treated with Teclistamab Outside of Clinical Trials
Clinical Lymphoma Myeloma & Leukemia·2024
P-048 Barriers to the Implementation of Bispecific Antibodies for Patient With Relapsed and Refractory Myeloma in the UK: Results of a National Survey
Clinical Lymphoma Myeloma & Leukemia·2024
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Blood Cancer Journal·2024· 9 citedOpen Access
Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir
Clinical Infectious Diseases·2023· 44 citedOpen Access
Dynamic Frailty Assessment in Transplant Non-Eligible Newly Diagnosed Myeloma Patients: Initial Data from UK Myeloma Research Alliance (UK-MRA) Myeloma XIV (FiTNEss): A Frailty-Adjusted Therapy Study
Blood·2023· 13 cited
Health-Related Quality of Life (HRQoL) in Fit, Unfit and Frail Patients Enrolled in Fitness (UK-MRA Myeloma XIV): A Cross Sectional Study
Blood·2023· 1 citedOpen Access
Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry
Research Square (Research Square)·2023· 1 citedOpen Access
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting
Clinical Lymphoma Myeloma & Leukemia·2023Open Access
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis
Amyloid·2023· 9 cited
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre <scp>UK</scp> retrospective analysis
British Journal of Haematology·2023· 6 citedOpen Access
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma <scp>XI’</scp>, a multicentre, open‐label, randomised, phase III trial
British Journal of Haematology·2022· 15 citedOpen Access
Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation
Annals of Hematology·2022· 3 cited
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort
PLoS ONE·2022· 7 citedOpen Access
<i>F</i> railty-adjusted therapy <i>i</i> n <i>T</i> ransplant <i>N</i> on- <i>E</i> ligible patient <i>s</i> with newly diagno <i>s</i> ed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial
BMJ Open·2022· 33 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Gordon Cook(25), Matthew Jenner(23), Mark T. Drayson(22), Charlotte Pawlyn(21), David A. Cairns(21), Martin Kaiser(21), Graham Jackson(20), Roger G. Owen(20), John R Jones(17), Faith E. Davies(16), Kamaraj Karunanithi(16), Walter M. Gregory(16), Mamta Garg(15), Jindriska Lindsay(15), Gareth J. Morgan(15), Alina Striha(12), Nigel H. Russell(11), Corinne Collett(9), Anna Hockaday(8), Emmanouil Nikolousis(8)